Bionime (TPE:4737) Research & Development: NT$355 Mil (TTM As of Dec. 2025)


TPE:4737 Bionime Corp TPE:4737
65 GF Score
Price NT$57.00
GF Value NT$58.96
Valuation Fairly Valued
! 7 Warning Signs
View Full Analysis

What is Bionime Research & Development?

Bionime TPE:4737 -0.18% 65 Research & Development is NT$355 Mil as of Dec. 2025. GuruFocus rates TPE:4737 with a GF Score™ of 65/100 and a GF Value™ of NT$58.96 (Fairly Valued). The stock has 7 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bionime's Research & Development for the three months ended in Dec. 2025 was NT$148 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$355 Mil.

Bionime  (TPE:4737) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bionime Research & Development Related Terms

Bionime Research & Development Historical Data

* Premium members only.

The historical data trend for Bionime's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bionime Research & Development Chart

Bionime Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 187.86 201.98 242.34 322.33 354.76

Bionime Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 66.61 78.11 55.00 74.05 147.59
TPE:4737
65GF Score
Bionime Corp TPE:4737
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bionime Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$355 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$355 Mil mean?
Bionime (TPE:4737) has a Research & Development of NT$355 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Bionime and its competitors.
Is Bionime's Research & Development too high?
Bionime's current Research & Development is NT$355 Mil. Overall, Bionime has a GF Score™ of 65/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bionime's Research & Development compare to ISRG and BDX?
Bionime's Research & Development of NT$355 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bionime and its competitors. Bionime's current Research & Development is NT$355 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionime stock overvalued right now?
Based on GuruFocus' analysis, Bionime (TPE:4737) is currently considered Fairly Valued. The stock's GF Value™ is NT$58.96, compared to a current price of NT$57.00 — trading 3.3% below its estimated fair value. The current Research & Development is NT$355 Mil. Bionime's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bionime (TPE:4737), the current Research & Development is NT$355 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bionime (TPE:4737) Overvalued in 2026?

Based on GuruFocus' analysis, Bionime stock appears to be undervalued. The current stock price of NT$57.00 is trading 3.3% below its estimated GF Value™ of NT$58.96. GuruFocus considers Bionime to be Fairly Valued.

Key valuation signals for TPE:4737:

  • Research & Development: NT$355 Mil
  • GF Value™: NT$58.96 vs. price of NT$57.00 (3.3% below fair value)
  • GF Score™: 65/100 with 7 warning signs

No single metric tells the full story. See the TPE:4737 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bionime Business Description

Address No. 100, Daqing Street, Section 2, South District, Taichung, TWN, 40242
Bionime Corp is engaged in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company's revenue is derived from the sale of blood glucose meters and test strips to domestic and foreign clients. Geographically, it operates in Algeria, China, Switzerland, the United States, Belarus, Egypt, the United Arab Emirates, and other countries, of which it derives the maximum revenue from Algeria.
65GF Score

Get the complete analysis for TPE:4737

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$57.00
Price
NT$58.96
GF Value